Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amber Shull

Physician Assistant, Medical Norton Shores, MI Physician Assistant

NPI 1770546749 CMS profile 10450192

131 W Seaway Dr, Norton Shores, MI 49444

Open in the dashboard

General payments

$153,913

1,189 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amber Shull of Norton Shores, MI is reported in the CMS Open Payments database as having received $153,913 across 1,189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38,223 224
2024 General $46,445 289
2023 General $43,852 278
2022 General $15,152 198
2021 General $10,242 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Shull
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Amber Shull were reported at $38,223. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Amber Shull Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $10,242 $156 $41–$563 $132
2022 $15,152 $185 $55–$649 $149
2023 $43,852 $199 $58–$717 $160
2024 $46,445 $206 $62–$740 $164
2025 $38,223 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $60,209 267 payments
  2. ITI, Inc. $39,728 196 payments
  3. Teva Pharmaceuticals USA, Inc. $28,176 158 payments
  4. Otsuka America Pharmaceutical, Inc. $17,026 71 payments
  5. Supernus Pharmaceuticals, Inc. $1,670 123 payments
  6. E.R. Squibb & Sons, L.L.C. $1,106 13 payments
  7. Alkermes, Inc. $685 36 payments
  8. Lundbeck LLC $599 37 payments
  9. Neurocrine Biosciences, Inc. $575 31 payments
  10. Corium, Inc. $518 55 payments
  11. Other $3,622 202 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $120,637 97 payments
  2. Food and Beverage $17,030 991 payments
  3. Travel and Lodging $10,257 95 payments
  4. Consulting Fee $5,935 4 payments
  5. Education $54 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $53,679 185 payments
  2. CAPLYTA Psychiatry $26,105 155 payments
  3. Austedo XR $25,785 95 payments
  4. REXULTI $16,938 65 payments
  5. CAPLYTA Psychiatry $13,623 41 payments
  6. VRAYLAR Neuroscience $5,461 24 payments
  7. AUSTEDO $2,239 47 payments
  8. Qelbree Viloxazine Hydrochloride $1,038 57 payments
  9. LINZESS $734 43 payments
  10. QELBREE Psychology $621 65 payments
  11. Other $11,357 650 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,311

Median for Physician Assistant: 241

Drug cost

$530,177

Median for Physician Assistant: $4,110

Branded share of claims

57.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 21 $162,092
Vraylar Cariprazine Hcl Brand 107 $145,155
Rexulti Brexpiprazole Brand 67 $95,601
Caplyta Lumateperone Tosylate Brand 38 $62,267
Trintellix Vortioxetine Hydrobromide Brand 32 $16,610
Auvelity Dextromethorphan Hbr/Bupropion Brand 14 $14,684
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 271 $11,420
Fluvoxamine Maleate Er Fluvoxamine Maleate Brand 12 $5,794
Mirtazapine Generic 75 $2,019
Paliperidone Er Paliperidone Brand 19 $1,831

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$5,487

Medicare's payments for the services billed

Medicare patients

16

Average age 57

Services billed

88

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$19,007 107 —
CAPLYTA
$14,240 38 —
Austedo XR
$7,594 21 —
REXULTI
$3,637 67 —
Qelbree
$543 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

1,189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record